

**Supplementary Table 2. Univariate analysis for 30-day and 60-day mortalities in overall patients after PS matching**

	No. of patients	Unadjusted OR (95% CI)	<i>p</i> value
<b>30-day mortality</b>			
Age	218	1.08 (1.04–1.12)	< 0.001
Male sex	130	0.72 (0.35–1.48)	0.360
Body mass index	218	1.00 (0.93–1.09)	0.925
Comorbidity	149	1.76 (0.79–4.36)	0.190
PaO <sub>2</sub> /FiO <sub>2</sub> at admission	218	1.00 (0.99–1.00)	0.111
Remdesivir	146	1.90 (0.85–4.68)	0.140
Vasopressor	82	6.93 (3.16–16.51)	< 0.001
Renal replacement therapy	34	7.29 (3.22–16.70)	< 0.001
Maximal dose of corticosteroid, mg	218	1.01 (1.00–1.01)	0.130
Ordinal clinical severity scale	218		0.002
3	75	Reference	
4	115	22.70 (4.66–409.83)	
5	28	29.60 (5.02–566.00)	
Duration of corticosteroid	218		0.013
Long-term users	109	Reference	
Short-term users	109	2.65 (1.23–5.71)	
<b>60-day mortality</b>			
Age	218	1.08 (1.05–1.12)	< 0.001
Male sex	130	0.84 (0.45–1.56)	0.570
Body mass index	218	1.03 (0.96–1.10)	0.438
Comorbidity	149	2.21 (1.09–4.80)	0.034
PaO <sub>2</sub> /FiO <sub>2</sub> at admission	218	1.00 (0.99–1.00)	0.312
Remdesivir	146	1.43 (0.74–2.88)	< 0.001
Vasopressor	82	7.68 (3.93–15.71)	< 0.001
Renal replacement therapy	34	14.26 (6.26–35.22)	< 0.001
Maximal dose of corticosteroid (mg)	218	1.01 (1.00–1.01)	0.120
Ordinal clinical severity scale	218		
3	75	Reference	< 0.001
4	115	17.31 (5.05–108.86)	
5	28	48.67 (11.95–334.30)	
Duration of corticosteroid	218		0.280
Long-term users	109	Reference	
Short-term users	109	1.41 (0.76–2.62)	

PS, propensity score; OR, odds ratio; CI, confidence interval; PaO<sub>2</sub>, partial pressure of oxygen; FiO<sub>2</sub>, fraction of inspired oxygen.